StrongBox Wealth LLC Has $640,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

StrongBox Wealth LLC lessened its stake in Zoetis Inc. (NYSE:ZTS) by 42.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,928 shares of the company’s stock after selling 2,910 shares during the quarter. StrongBox Wealth LLC’s holdings in Zoetis were worth $640,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. State Street Corp increased its stake in Zoetis by 0.5% in the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company’s stock valued at $3,864,488,000 after buying an additional 95,856 shares during the period. Geode Capital Management LLC increased its stake in Zoetis by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock valued at $2,030,813,000 after buying an additional 185,364 shares during the period. Mizuho Securities USA LLC increased its stake in Zoetis by 13,726.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after buying an additional 4,829,815 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Zoetis by 5.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock worth $761,221,000 after purchasing an additional 194,542 shares during the last quarter. Finally, Clearbridge Investments LLC increased its stake in shares of Zoetis by 5.8% during the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock worth $527,774,000 after purchasing an additional 166,517 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $167.23 on Thursday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The firm has a fifty day moving average price of $171.31 and a two-hundred day moving average price of $180.16. The company has a market cap of $75.45 billion, a PE ratio of 31.43, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the prior year, the firm earned $1.36 EPS. The business’s revenue was up 11.6% on a year-over-year basis. Analysts expect that Zoetis Inc. will post 5.91 EPS for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. Zoetis’s dividend payout ratio is 32.52%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Stifel Nicolaus dropped their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Leerink Partners assumed coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has an average rating of “Buy” and an average target price of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.